Entities / Company
ALK-Abelló.
Danish pharmaceutical company
- Reports this week
- 1
- Active events
- 1
- Connections
- 29
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Active this week
One to three months ago
-
Supply of auto-injectors is facing shortages, coinciding with reports that severe allergies affect 300,000 people in Austria.Some support1 report
-
NICE recommended ALK-Abelló's allergy tablets, which are now available through the National Health Service.Some support1 report
-
ALK-Abelló received approval from Health Canada and launched its product neffy in the Canadian market.Some support1 report
Gone quiet
No new reports in 90+ daysNo events began in the chosen period. Widen it, or reset.
Around ALK-Abelló this week
News at the entities that move ALK-Abelló most-
Health Canada StructuralMurray founded Shoppers Drug Mart in Canada, while Greentank uses Intel Inside and Health Canada is a government department.Moves ALK-Abelló
-
Denmark Shared contextDenmark is supporting training activities for the Kenya Navy.Moves ALK-Abelló
-
National Health Service StructuralMatthew Hopkins has been appointed director for acute care of NHS Alliance, with services mandated to be organized across England.Moves ALK-Abelló
Connections
The 6 strongest of 29, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Edward Jordan Structural
Edward Jordan holds the executive vice president role for ALK North America.
-
Health Canada Structural
Health Canada grants regulatory approval to ALK-Abelló, establishing a formal regulatory dependency for market access.
-
National Health Service Structural
ALK-Abelló supplies products (tablets) that are procured and made available through the National Health Service.
-
NICE formally recommended ALK-Abelló's allergy tablets, influencing their market access in the UK.
-
Denmark Shared context
ALK-Abelló is located and operates within Denmark.
-
Changchun Shared context
ALK-Abelló conducted a Phase 3 clinical trial within the geographic context of China.
History
Events by the month they beganOctober 2026
1 eventAugust 2026
3 events- Supply of auto-injectors is facing shortages, coinciding with reports that severe allergies affect 300,000 people in Austria.
- NICE recommended ALK-Abelló's allergy tablets, which are now available through the National Health Service.
- ALK-Abelló received approval from Health Canada and launched its product neffy in the Canadian market.